Pin to quick picksSummit Ther Regulatory News (SUMM)

Share Price Information for Summit Ther (SUMM)

London Stock Exchange
Share Price: 20.00
Bid: 19.00
Ask: 21.00
Change: 0.00 (0.00%)
Spread: 2.00 (10.53%)
Open: 20.00
High: 20.00
Low: 19.00
Yest. Close: 20.00
SUMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.
Date   Source Headline
1st Aug 201912:00 pmREUSummit Therapeutics to Present at the Canaccord Genuity Growth Conference
17th Jul 201912:00 pmREUSummit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress
9th Jul 201912:00 pmREUSummit’s DDS-04 Enterobacteriaceae Programme Demonstrates In Vivo Efficacy in Sepsis and Pneumonia
20th Jun 201912:00 pmREUSummit to Present on Pipeline and Strategy for its New Classes of Antibiotics at ASM Microbe 2019
19th Jun 201912:00 pmREUResult of AGM
18th Jun 201912:00 pmREUIncreased BARDA Award and Option Exercise
12th Jun 201912:00 pmREUSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
5th Jun 20192:00 pmREUNotice of First Quarter Results
14th May 20195:30 pmREUUK Annual Report and Notice of AGM
29th Apr 201912:30 pmREUBlock Listing Interim Review
24th Apr 20194:20 pmREUExercise of Restricted Stock Units
15th Apr 20197:00 amREUSummit Presents In Vivo Proof of Concept Data for New Mechanism Antibiotics Targeting Enterobacteriaceae in Oral Session at ECCMID 2019
3rd Apr 201912:00 pmREUSummit’s Pipeline Expands with Series of New Mechanism Antibiotics Targeting Enterobacteriaceae
2nd Apr 201912:00 pmREUSummit Therapeutics to Present at H. C. Wainwright & Co. Global Life Sciences Conference
29th Mar 20195:45 pmREUAward of Share Options
29th Mar 201911:15 amREUFiling of Annual Report on Form 20-F
27th Mar 201911:00 amREUFinal Results
25th Mar 201911:00 amREUNotice of Results
18th Mar 201911:00 amREUSummit Therapeutics to Present at Upcoming Conferences
14th Mar 201911:00 amREUSummit Highlights Use of Discuva Platform in Identifying New Mechanism Antibiotics against Neisseria Gonorrhoeae and ESKAPE Pathogens at Novel Antimicrobials and AMR Diagnostics 2019 Conference
25th Feb 201912:00 pmREUSummit’s SMT-571 Potent Against Over 200 Clinical Isolates of Neisseria Gonorrhoeae, Including Numerous Multi- and Extensively-Drug Resistant Strains, in Published Preclinical Data
13th Feb 201912:00 pmREUSummit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
8th Feb 201912:00 pmREUSummit Therapeutics to Present at the BIO CEO & Investor Conference
15th Jan 20195:45 pmREUHolding(s) in Company
14th Jan 201912:00 pmREUAward of Restricted Stock Units
10th Jan 20194:15 pmREUHolding(s) in Company
10th Jan 201911:30 amREUHolding(s) in Company
10th Jan 20197:00 amREUCompletion of $25 million Subscription
9th Jan 20194:45 pmREUHolding(s) in Company
8th Jan 20197:00 amREUUpdate on Admission
4th Jan 201912:30 pmREUResult of General Meeting
2nd Jan 20199:40 amREUHolding(s) in Company
11th Dec 201812:00 pmREU3rd Quarter Results
6th Dec 201812:00 pmREUSummit Therapeutics to Report Financial Results for the Third Quarter and Nine Months Ended 31 October 2018 on 11 December 2018
30th Nov 20181:30 pmREUHolding(s) in Company
7th Nov 201812:00 pmREUSummit Therapeutics to Participate in Jefferies 2018 London Healthcare Conference
1st Nov 20184:34 pmREUHolding(s) in Company
1st Nov 201811:00 amREUSummit Recognises C. difficile Awareness Month
24th Oct 20184:15 pmREUDirector/PDMR Shareholding
10th Oct 201812:00 pmREUSummit Therapeutics to Participate in Upcoming Investor Events
3rd Oct 201812:00 pmREUSummit Highlights Phase 3-Ready Precision Antibiotic Ridinilazole at IDWeek 2018
1st Oct 20183:00 pmREUBlock listing Interim Review
26th Sep 201812:00 pmREUSummit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disease at ID Week 2018
20th Sep 201812:00 pmREUSummit Reports Financial Results for the Second Quarter Ended 31 July 2018 and Operational Progress
14th Sep 201812:00 pmREUSummit Therapeutics to Participate in Upcoming Investor Conferences
14th Sep 201812:00 pmREUSummit Therapeutics to Report Financial Results for the Second Quarter and Half Year Ended 31 July 2018 on 20 September 2018
6th Sep 201812:00 pmREUSummit Discovers Multiple New Mechanism Antibiotics Against Novel ESKAPE Pathogen Targets
5th Sep 201812:00 pmREUSummit Nominates New Mechanism Antibiotic SMT-571 as its Lead Clinical Candidate for the Treatment of Gonorrhoea
3rd Sep 201811:00 amREUTotal voting rights
29th Aug 201812:00 pmREUSummit Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference

Login to your account

Don't have an account? Click here to register.